Alesta Therapeutics B.V.

The sponsor concentrates on developing therapeutic interventions for hypophosphatasia, a rare inherited metabolic bone disorder characterized by defective bone and tooth mineralization. This condition results from mutations affecting alkaline phosphatase activity, leading to significant skeletal abnormalities and complications across the lifespan.

• Hypophosphatasia treatment development
• Oral therapeutic formulations for rare bone diseases
• Bone mineralization disorders

The research addresses a critical unmet medical need in the field of rare genetic disorders, focusing on novel approaches to restore normal bone metabolism and improve patient outcomes in this challenging condition.